PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations

More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy, researchers from the Abramson Cancer Center (ACC) at the University of Pennsylvania reported online today in the Journal of Clinical Oncology. The …